D. Gillatt

发表

SERINE ARGININE PROTEIN KINASE-1 (SRPK1) INHIBITION AS A POTENTIAL NOVEL TARGETED THERAPEUTIC STRATEGY IN PROSTATE CANCER

J. Oxley, Athina Mavrou, K. Brakspear, 2014, Oncogene.

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

T. Peters, J. Oxley, F. Hamdy, 2020, Health technology assessment.

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

David Gillatt, Richard M Martin, John Staffurth, 2017, The New England journal of medicine.

Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

David Gillatt, Edward Rowe, Chris Metcalfe, 2016, The New England journal of medicine.

The use of prostate-specific antigen testing in the detection of localized prostate cancer

F. Hamdy, J. Donovan, D. Gillatt, 2000 .

VEGF 165 b , an Inhibitory Splice Variant of Vascular Endothelial Growth Factor , Is Down-Regulated in Renal Cell Carcinoma 1

D. Gillatt, S. Harper, D. Bates, 2002 .

Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes.

D. Gillatt, S. Harper, D. Bates, 2003, American journal of physiology. Renal physiology.

Lymphoedema in urological cancer.

D. Gillatt, D. Bates, A. Okeke, 2004, European urology.

Management Options for Gynaecomastia and Breast Pain Associated with Nonsteroidal Antiandrogen Therapy

D. Gillatt, M. Wirth, W. See, 2012, Clinical drug investigation.

Pilot study of screening for prostate cancer in general practice

D. Gillatt, T. Kemple, J. Astley, 1991, The Lancet.

Who is at risk of death from nephrectomy? An analysis of thirty‐day mortality after 21 380 nephrectomies in 3 years of the British Association of Urological Surgeons (BAUS) National Nephrectomy Audit

P. Dasgupta, A. Henderson, D. Nicol, 2017, BJU international.

Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy

D. Gillatt, W. Duan, Yong Li, 2016, Oncotarget.

The feasibility of Miltuximab®-IRDye700DX-mediated photoimmunotherapy of solid tumors.

D. Gillatt, A. Zvyagin, D. Polikarpov, 2020, Photodiagnosis and photodynamic therapy.

Editorial

D. Gillatt, 2010 .

BJU International: Editorial

D. Gillatt, 2010 .

Cancer stem cells and signaling pathways in radioresistance

D. Gillatt, Yong Li, J. Bucci, 2015, Oncotarget.

Magnetic resonance imaging in the staging of bladder cancer.

D. Gillatt, P. Smith, R. Persad, 1993, British journal of urology.

Advanced prostate cancer: Hormones and beyond

D. Gillatt, B. Tombal, L. Klotz, 2007 .

Treatment options in prostate cancer once primary therapy fails

D. Gillatt, B. Tombal, H. Payne, 2007 .

Surgical management of localised prostate cancer

D. Gillatt, G. Nabi, M. Shelley, 2011 .

Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel

D. Gillatt, J. Holly, R. Persad, 2011, British Journal of Cancer.

Lipoprotein levels following treatment with cyproterone acetate or LHRH analogues.

D. Gillatt, D. Chadwick, J. Gingell, 1993, British journal of urology.

Can diet affect prostate cancer?

D. Gillatt, J.‐P. Meyer, 2002, BJU international.

Prediction of prostate cancer in extended‐field biopsies of the prostate

D. Gillatt, E. Kulinskaya, M. Winkler, 2004, BJU international.

The Melbourne Consensus Statement on the early detection of prostate cancer

T. Ahlering, M. Cooperberg, M. Gleave, 2014, BJU international.

D. Gillatt, L. Michala, D. Wood, 2020, World Journal of Urology.

Treatment of prostatic cancer

D. Gillatt, P. Smith, J. Gingell, 1988, British medical journal.

Medical or surgical orchidectomy: the patients' choice.

D. Gillatt, D. Chadwick, J. Gingell, 1991, BMJ.

Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array

J. R. Wilson, David M. Holden, P. W. Foster, 2016, British Journal of Cancer.

VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.

D. Gillatt, S. Harper, D. Bates, 2002, Cancer research.

Year Outcomes after Monitoring , Surgery , or Radiotherapy for Localized Prostate Cancer

T. Peters, J. Oxley, F. Hamdy, 2016 .

Haematuria Analysed – a Prospective Study

D. Gillatt, P. O’Reilly, 1987, Journal of the Royal Society of Medicine.

The Risk of Prostate Cancer amongst Black Men in the United Kingdom: The PROCESS Cohort Study

D. Gillatt, D. Dorling, Y. Ben-Shlomo, 2008 .

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial

T. Peters, J. Oxley, F. Hamdy, 2017, Journal of clinical epidemiology.

Metastatic renal oncocytoma

J. Oxley, D. Gillatt, A. Mitchelmore, 2007, Journal of Clinical Pathology.

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial

J. Oxley, F. Hamdy, D. Neal, 2017, European urology.

Clinical presentation and initial management of Black men and White men with prostate cancer in the United Kingdom: the PROCESS cohort study

D. Gillatt, Y. Ben-Shlomo, C. Metcalfe, 2009, British Journal of Cancer.

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression

J. Oxley, M. Varma, F. Hamdy, 2020, BJU international.

The risk of prostate cancer amongst South Asian men in southern England: the PROCESS cohort study

D. Gillatt, D. Dorling, Y. Ben-Shlomo, 2008, BJU international.

Measurement of the insulin-like growth factor (IGF)-axis does not enhance the specificity of PSA-based prostate cancer screening.

T. Peters, F. Hamdy, D. Neal, 2002 .

Magnetic Resonance Imaging of Spinal Metastases

D. Gillatt, D. Chadwick, J. Gingell, 1991, Journal of the Royal Society of Medicine.

Prostate-specific antigen and prognosis in patients with metastatic prostate cancer--a multivariable analysis of prostate cancer mortality.

T. Peters, D. Gillatt, J. Reynard, 1995, British journal of urology.

Managing the warfarinized urological patient

D. Gillatt, R. Persad, R. Lush, 2003, BJU international.

BCG immunotherapy for superficial bladder cancer

D. Gillatt, C. Lockyer, 2001, Journal of the Royal Society of Medicine.

Contemporary update of cancer control after radical prostatectomy in the UK

D. Gillatt, R. Persad, M. Winkler, 2004, British Journal of Cancer.

Hereditary urological cancer syndromes

D. Gillatt, K. Jefferson, 2007, Nature Clinical Practice Urology.

The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study.

David Gillatt, Raj Persad, Yoav Ben-Shlomo, 2007, European urology.

Safety and tolerability of Miltuximab® - a first in human study in patients with advanced solid cancers.

D. Bailey, D. Gillatt, D. Sabanathan, 2021, Asia Oceania journal of nuclear medicine & biology.

Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2.

D. Gillatt, L. Zeng, J. Holly, 2013, Endocrine-related cancer.

Trends in operative caseload and mortality rates after radical cystectomy for bladder cancer in England for 1998-2010.

D. Gillatt, J. Verne, J. McGrath, 2015, European urology.

Histological and Environmental Changes in Longstanding Ileal Conduits

D. Gillatt, P. Smith, J. Hammonds, 1990, Journal of the Royal Society of Medicine.

Are diet-prostate cancer associations mediated by insulin-like growth factors? Cross-sectional analysis of diet-IGF associations in middle-aged men

T. Peters, F. Hamdy, J. Donovan, 2002 .

Erectile function post robotic radical prostatectomy: technical tips to improve outcomes?

D. Gillatt, R. Persad, S. Goonewardene, 2016, Journal of Robotic Surgery.

Erectile Function Post Robotic Radical Prostectomy: What are the Technical Tips and Tricks?

D. Gillatt, R. Persad, Goonewardene Ss, 2016 .

Erythrocyte stearic to oleic acid ratio in prostatic carcinoma.

D. Gillatt, N. Habib, P. Smith, 1990, British journal of urology.

Flower Pollen Extract and its Effect on the Prostate Alternative medications for benign prostatic hyperplasia available on the Internet : a review of the evidence for their use

D. Gillatt, J.‐P. Meyer, 2017 .

Pharmacodynamics of a long acting depot preparation of avorelin in patients with prostate cancer. Avorelin Study Group.

D. Gillatt, B. Imbimbo, P. Malone, 1999, The Journal of urology.

Testicular Sparing Surgery: Is there a Role in Management of Bilateral Orchidectomy?

D. Gillatt, N. Lawrentschuk, D. Bolton, 2016 .

High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.

D. Gillatt, P. Smith, M. A. Ferro, 1989, Urology.

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)

Catherine J. Grey, Susan N Moore, P. Fayers, 2022, Bju International.

Ketamine-associated lower urinary tract destruction: a new radiological challenge.

D. Gillatt, A. Mitchelmore, A. Cottrell, 2010, Clinical radiology.

Robot‐assisted radical cystectomy with intracorporeal urinary diversion: impact on an established enhanced recovery protocol

D. Gillatt, E. Rowe, A. Koupparis, 2015, BJU international.

Introduction of an enhanced recovery protocol for radical cystectomy

D. Gillatt, K. Jefferson, N. Arumainayagam, 2008, BJU international.

Ketamine cystitis as a mimic of carcinoma in situ

J. Oxley, D. Gillatt, S. Adams, 2009, Histopathology.

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study.

D Gillatt, F. Hamdy, J. Donovan, 2003, Health technology assessment.

A systematic review of PFE pre-prostatectomy

D. Gillatt, R. Persad, S. Goonewardene, 2018, Journal of Robotic Surgery.

Prostate Cancer Survivorship and Psychosexual Care: A Systematic Review for a Continuously Evolving Field

D. Gillatt, R. Persad, A. Young, 2016 .

Robotic radical cystectomy - revision and resection: An evolution in operative technique and platforms.

D. Gillatt, R. Persad, S. Goonewardene, 2017, European journal of cancer care.

Conservative Surgery for Early Breast Cancer

R. Laing, D. Gillatt, Mrcp, 1989, Bristol medico-chirurgical journal.

Improvement of an Enhanced Recovery Protocol for Radical Cystectomy

D. Gillatt, E. Rowe, A. Koupparis, 2010 .

VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant

Marina Ziche, Lucia Morbidelli, Yan Qiu, 2004, Cancer Research.

Vaccine requirements compete with basic needs of poor people

D. Gillatt, A. Cottrell, Kate Warren, 2008, BMJ : British Medical Journal.

THE DESTRUCTION OF THE LOWER URINARY TRACT BY KETAMINE ABUSE: A NEW SYNDROME?

D. Gillatt, A. Cottrell, Vivek Kumar, 2008, BJU international.

Consider ketamine misuse in patients with urinary symptoms.

D. Gillatt, A. Cottrell, 2008, The Practitioner.

Pathological analysis of lymph nodes in anterior prostatic fat excised at robot-assisted radical prostatectomy

J. Oxley, D. Gillatt, E. Rowe, 2014, Journal of Clinical Pathology.

Detection of rare prostate cancer cells in human urine offers prospect of non-invasive diagnosis

D. Gillatt, N. Packer, R. Willows, 2022, Scientific Reports.

PSA recurrence following radical prostatectomy is comparable for all age groups in the UK

D. Gillatt, M. Winkler, G. Boustead, 2005, Prostate Cancer and Prostatic Diseases.

A three‐centre experience of orthotopic neobladder reconstruction after radical cystectomy: initial results

D. Gillatt, R. Persad, Brent Drake, 2004, BJU international.

Magnetic resonance imaging in the staging of renal cell carcinoma.

D. Gillatt, R. Persad, J. Kabala, 1991, The British journal of radiology.

The effect of erectile dysfunction on the quality of life of men after radical prostatectomy

D. Gillatt, R. MacDonagh, R. Lockyer, 2003, BJU international.

Is intravesical chemotherapy for superficial bladder cancer still justified?

D. Gillatt, A. Okeke, H. Schwaibold, 2005, BJU international.

Delayed diagnosis of traumatic rupture of the spleen--a warning of the use of thoracic epidural analgesia in chest trauma.

D. Gillatt, A. J. Ward, 1989, Injury.

Rapid and Label-Free Isolation of Tumour Cells from the Urine of Patients with Localised Prostate Cancer Using Inertial Microfluidics

David Gillatt, Sajad Razavi Bazaz, Majid Ebrahimi Warkiani, 2019, Cancers.

Appraising risk in active surveillance of localized prostate cancer

D. Gillatt, F. Rapport, K. Churruca, 2019, Health expectations : an international journal of public participation in health care and health policy.

Massive bladder calculus as a complication of a titanium prostatic stent.

D. Gillatt, B. Squires, 1995, British journal of urology.

Use of bacille Calmette-Guérin in superficial bladder cancer

D. Gillatt, R. Persad, J.‐P. Meyer, 2002, Postgraduate medical journal.

A peculiar case of granulomatous prostatitis: a cause for concern.

D. Gillatt, S. Gujral, 1998, British journal of urology.

Localised and Locally Advanced Prostate Cancer: Who to Treat and How?

D. Gillatt, K. Miller, L. Klotz, 2007 .

Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.

J. Oxley, D. Gillatt, M. Trivella, 1999, The Journal of urology.

Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells

Shereen R Kadir, J. Oxley, D. Gillatt, 2010, Nature Cell Biology.

Proteomics discovery of radioresistant cancer biomarkers for radiotherapy.

D. Gillatt, Yong Li, J. Bucci, 2015, Cancer letters.

ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer

F. Hamdy, D. Neal, J. Donovan, 2018, Cancer Prevention Research.

Complications of T-tube drainage of the common bile duct.

D. Gillatt, R. May, R. E. May, 1985, Annals of the Royal College of Surgeons of England.

The status of surgery in the management of high-risk prostate cancer

D. Gillatt, C. Bach, E. Rowe, 2014, Nature Reviews Urology.

Communicating risk in active surveillance of localised prostate cancer: a protocol for a qualitative study

D. Gillatt, F. Rapport, K. Churruca, 2017, BMJ Open.

Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein.

D. Gillatt, S. Harper, D. Bates, 2004, American journal of physiology. Renal physiology.

Recreational ketamine: from pleasure to pain

D. Gillatt, J. Southgate, S. Baker, 2011, BJU international.

Beware the BCG failures: a review of one institution's results.

D. Gillatt, J. Sedgwick, C. Lockyer, 2002, European urology.

A Single Institution's 10 Year Experience of Treating High Grade Superficial Transitional Cell Carcinoma and Carcinoma In Situ of the Bladder with Intravesical BCG

D. Gillatt, R. Persad, Jon‐Paul Meyer, 2002 .

Initial human clinical experience with diode laser interstitial treatment of benign prostatic hyperplasia.

D Gillatt, J J de la Rosette, D. Gillatt, 1996, Urology.

Robotic-assisted magnetic resonance imaging ultrasound fusion results in higher significant cancer detection compared to cognitive prostate targeting in biopsy naive men

D. Gillatt, P. Vladica, Manish I. Patel, 2020, Translational andrology and urology.

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.

T. Peters, P. Fayers, D. Aston, 2019, European urology.

Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study.

H. G. van der Poel, P. Dasgupta, A. Mottrie, 2021, Urologic oncology.

Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches.

H. G. van der Poel, P. Dasgupta, A. Mottrie, 2019, The Journal of urology.

Diagnosis, management and screening of early localised prostate cancer.

J. Donovan, D. Gillatt, J. Coast, 1997, Health technology assessment.

Seminal vesicle carcinoma

D. Gillatt, P. Burton, M. Brett, 1999, Histopathology.

Optimal Nutrition Should Improve the Outcome and Costs of Radical Cystectomy

D. Gillatt, R. Thurairaja, R. Persad, 2006, Urologia Internationalis.

Changes in patient characteristics and outcomes for radical cystectomy in England

D. Gillatt, M. Emberton, J. H. van der Meulen, 2005, BJU international.

Expression of neuropilin-1 by human glomerular epithelial cells in vitro and in vivo.

D. Gillatt, S. Harper, P. Mathieson, 2001, Clinical science.

Ethanol‐glycine irrigating fluid for transurethral resection of the prostate in practice

D. Gillatt, D. Dickerson, A. Hinchliffe, 2000, BJU international.

Current and Future Trends in the Treatment of Renal Cancer

D. Gillatt, C. Evans, A. Tubaro, 2007 .

High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial

David P. Smith, M. Fenech, V. Gebski, 2021, BMJ Open.

Abdominal aortic aneurysms presenting as renal colic.

D. Gillatt, S. Eckford, 1992, British journal of urology.

Serum Insulin-Like Growth Factor-I Is Positively Associated with Serum Prostate-Specific Antigen in Middle-Aged Men without Evidence of Prostate Cancer

T. Peters, F. Hamdy, D. Neal, 2004, Cancer Epidemiology Biomarkers & Prevention.

The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice

E. Kleinerman, D. Gillatt, S. Harper, 2008, British Journal of Cancer.

Development of a complex intervention improved randomization and informed consent in a randomized controlled trial.

T. Peters, F. Hamdy, D. Neal, 2009, Journal of Clinical Epidemiology.

Ductal carcinomas of the prostate: a clinicopathological and immunohistochemical study.

J. Oxley, D. Gillatt, C. Abbott, 1998, British journal of urology.

Are diet–prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men

T. Peters, F. Hamdy, D. Neal, 2003, British Journal of Cancer.

Screen‐detected prostate cancer and the insulin‐like growth factor axis: Results of a population‐based case‐control study

T. Peters, F. Hamdy, D. Neal, 2004, International journal of cancer.

Glypican‐1 as a target for fluorescence molecular imaging of bladder cancer

D. Gillatt, G. Palapattu, A. Zvyagin, 2021, International journal of urology : official journal of the Japanese Urological Association.

Thromboembolic events with cisplatin-based neoadjuvant chemotherapy for transitional cell carcinoma of urinary bladder.

D. Gillatt, E. Rowe, R. Persad, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiandrogen treatments in locally advanced prostate cancer: are they all the same?

D. Gillatt, 2006, Journal of Cancer Research and Clinical Oncology.

A description of radical nephrectomy practice and outcomes in England: 1995–2002

David Gillatt, Jan van der Meulen, Martin Nuttall, 2005, BJU international.

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

Joyce E. Wilkinson, T. Peters, P. Fayers, 2016, BJU international.

Threshold volumes for urological cancer surgery: a survey of UK urologists

D. Gillatt, M. Emberton, J. H. van der Meulen, 2004, BJU international.

The prevalence and natural history of urinary symptoms among recreational ketamine users

D. Gillatt, A. Winstock, L. Mitcheson, 2012, BJU International.

Dialysis in patients with upper urinary tract transitional cell carcinoma.

D. Gillatt, R. Persad, P. Harrison, 1992, British journal of urology.

Interstitial laser coagulation in the treatment of benign prostatic hyperplasia using a diode-laser system with temperature feedback.

D. Gillatt, J. J. de la Rosette, R. Muschter, 1997, British journal of urology.

A three‐centre experience of orthotopic neobladder reconstruction after radical cystectomy: revisiting the initial experience, and results in 104 patients

D. Gillatt, R. Persad, C. Blick, 2009, BJU international.

A systematic review and critique of the literature relating hospital or surgeon volume to health outcomes for 3 urological cancer procedures.

D. Gillatt, M. Emberton, J. H. van der Meulen, 2004, The Journal of urology.

Epidemiology of transitional cell carcinoma of the bladder: profile of an urban population in the south-west of England.

D. Gillatt, P. Smith, R. Persad, 1998, British journal of urology.

Prostate cancer - evidence of exercise and nutrition trial (PrEvENT): study protocol for a randomised controlled feasibility trial

J. Oxley, D. Gillatt, P. Abrams, 2016, Trials.

Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.

T. Peters, F. Hamdy, D. Neal, 2004, Urology.

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).

T. Peters, F. Hamdy, D. Neal, 2003, Journal of clinical epidemiology.

Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells

D. Gillatt, A. Zvyagin, D. Polikarpov, 2019, Biomolecules.

Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach

D. Gillatt, Yong Li, J. Bucci, 2017, Scientific Reports.

Time from diagnosis to surgery and prostate cancer survival: a retrospective cohort study

D. Gillatt, Richard M. Martin, J. Wade, 2013, BMC Cancer.

T. Peters, F. Hamdy, D. Neal, 2004, The Journal of clinical endocrinology and metabolism.

Incidence, Predictive Factors and Preventive Measures for Inguinal Hernia following Robotic and Laparoscopic Radical Prostatectomy: A Systematic Review

D. Gillatt, S. Leslie, N. Ahmadi, 2019, The Journal of urology.

Learning curve and stage migration of a radical retropubic prostatectomy series over a 10-y period

D. Gillatt, M. Winkler, M. Winkler, 2004, Prostate Cancer and Prostatic Diseases.

Time trends in case selection, stage and prostate‐specific antigen recurrence after radical prostatectomy: a multicentre audit

D. Gillatt, R. Persad, M. Winkler, 2004, BJU international.

Pathways to diagnosis for Black men and White men found to have prostate cancer: the PROCESS cohort study

D. Gillatt, Y. Ben-Shlomo, C. Metcalfe, 2008, British Journal of Cancer.

Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment

J. Oxley, F. Hamdy, D. Neal, 2023, NEJM Evidence.

Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.

J. Oxley, D. Gillatt, M. Ladomery, 2014, American journal of clinical pathology.

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)

D. Aston, J. Oxley, F. Hamdy, 2022, BJU international.

A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence.

D. Gillatt, M. Beresford, R. Benson, 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial

T. Peters, F. Hamdy, D. Neal, 2020, BMJ Open.

Initial management of low‐risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry

C. Parker, D. Gillatt, S. McPhail, 2010, BJU international.

A comparison of endorectal magnetic resonance imaging and transrectal ultrasonography in the local staging of prostate cancer with histopathological correlation.

D. Gillatt, M. Speakman, T S Bates, 1997, British journal of urology.

Men’s experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study

T. Peters, D. Neal, J. Donovan, 2021, Cancer Causes & Control.

Systematic review of the safety and efficacy of osseointegration prosthesis after limb amputation

D. Gillatt, A. Blom, S. Kunutsor, 2018, The British journal of surgery.

IGFBP-2 acts as a tumour suppressor and plays a role in determining chemosensitivity in bladder cancer cells

D. Gillatt, E. Rowe, J. Holly, 2019, Oncotarget.

Contemporary radical cystectomy outcomes in patients with invasive bladder cancer: a population‐based study

David P. Smith, D. Gillatt, Manish I. Patel, 2015, BJU international.

Her-2/neu oncogene amplification in clinically localised prostate cancer.

J. Oxley, D. Gillatt, M. Winkler, 2002, Journal of clinical pathology.

Orthotopic neobladder reconstruction – what are the options?

D. Gillatt, R. Persad, Jon‐Paul Meyer, 2005, BJU international.

A DELAY IN RADICAL CYSTECTOMY OF >3 MONTHS IS NOT ASSOCIATED WITH A WORSE CLINICAL OUTCOME

D. Gillatt, J. Verne, R. Persad, 2008, BJU international.

Computer-assisted cystoscopy diagnosis of bladder cancer.

Ewa M Goldys, D. Gillatt, E. Goldys, 2018, Urologic oncology.

Managing patients with acute urinary retention.

D. Gillatt, S. Kuppusamy, 2011, Practitioner.

Advanced prostate cancer: what's new in hormonal manipulation?

D. Gillatt, S. Brewster, 1993, British journal of hospital medicine.

197 THE RELATIONSHIP OF CHRONIC RECREATIONAL KETAMINE USE AND SEVERE BLADDER PATHOLOGY: PRESENTATION, MANAGEMENT OF SYMPTOMS AND PUBLIC HEALTH CONCERNS

D. Gillatt, A. Cottrell, Kate Warren, 2009 .

Nerve hyperplasia: a unique feature of ketamine cystitis

J. Oxley, D. Gillatt, J. Southgate, 2013, Acta neuropathologica communications.

What is the 'normal range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker.

D. Gillatt, J. Reynard, 1995, British journal of urology.

120 PROGNOSTIC FACTORS FOR UPPER TRACT TRANSTITONAL CELL CARCINOMA AND METACHRONOUS UROTHELIAL TUMOURS: EVALUATING 888 PATIENTS FROM THE BAUS SECTION OF ONCOLOGY UROLOGICAL CANCER OBSERVATORY PROJECT

D. Gillatt, R. Kockelbergh, R. Persad, 2009 .

Development and evaluation of the MiCheck test for aggressive prostate cancer.

D. Chan, D. Gillatt, J. Ruterbusch, 2020, Urologic oncology.

Robotic radical cystectomy: intracorporeal versus extracorporeal versus orthotopic neobladder—Which is better?

D. Gillatt, R. Persad, S. Goonewardene, 2016, World Journal of Urology.

The Treatment of High Grade Superficial Bladder Cancer and Carcinoma In Situ with BCG -- A Questionnaire Survey of Consultant Practice in England and Wales

D. Gillatt, R. Persad, J.‐P. Meyer, 2002 .

Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab®-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery

D. Gillatt, A. Zvyagin, S. Deyev, 2020, Cancers.

Differences and commonalities in the management of locally advanced prostate cancer: results from a survey of oncologists and urologists in the UK

D. Gillatt, H. Payne, 2007, BJU international.

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

J. Oxley, F. Hamdy, D. Neal, 2023, The New England journal of medicine.

Prevalence and Impact of Incontinence and Impotence following Total Prostatectomy Assessed Anonymously by the ICS-Male Questionnaire

D. Gillatt, T. S. Bates, M. Wright, 1998, European Urology.

p53 and bcl‐2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy

J. Oxley, D. Gillatt, S. Brewster, 2002, BJU international.

RECOVERY OF ERECTILE FUNCTION AFTER NERVE‐SPARING RADICAL PROSTATECTOMY: IMPROVEMENT WITH NIGHTLY LOW‐DOSE SILDENAFIL

D. Gillatt, R. Persad, A. Mevcha, 2009, BJU international.

Case selection for radical prostatectomy in the UK.

D. Gillatt, R. Persad, M. Winkler, 2004, European urology.

Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom

D Gillatt, F. Hamdy, J. Donovan, 1999, BMJ.

Is it worth to perform radical prostatectomy in a salvage setting? Results of a contemporary multicentre series of 395 cases

P. Dasgupta, A. Mottrie, D. Gillatt, 2018 .

Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2

D. Gillatt, J. Holly, R. Persad, 2016, Endocrine-related cancer.

Implementation of consensus-based perioperative care pathways to reduce clinical variation for elective surgery in an Australian private hospital: a mixed-methods pre–post study protocol

J. Braithwaite, D. Gillatt, K. Churruca, 2023, BMJ Open.

Cardiopulmonary reserve as determined by cardiopulmonary exercise testing correlates with length of stay and predicts complications after radical cystectomy

D. Gillatt, P. White, J. Angell, 2015, BJU international.

Polydioxanone suture in the gastrointestinal tract.

D. Gillatt, D. Leaper, D. Bartolo, 1987, Annals of the Royal College of Surgeons of England.

Secondary carcinomatous infiltration of the penis: palliation with radiotherapy

D. Gillatt, Stephen G. Oswald, Mr D. A. Gillatt, 1985, The British journal of surgery.

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial

F. Hamdy, D. Neal, J. Donovan, 2020, BMC Cancer.

Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance.

Susan N Moore, P. Fayers, D. Aston, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

Ketamine-Associated Urinary Tract Pathology: The Tip of the Iceberg for Urologists?

D. Gillatt, A. Cottrell, 2008 .

Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer—a pilot study

D. Gillatt, M. Sugiono, M. Benney, 2005, Prostate Cancer and Prostatic Diseases.

A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome.

D. Gillatt, R. Kirby, M. Feneley, 1996, British Journal of Urology.

Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.

J. Oxley, D. Gillatt, M. Ladomery, 2014, American journal of clinical pathology.

Outcomes of the miltuximab first in human trial and proposed study design for a phase I trial 89Zr/177Lu theranostic trial.

D. Bailey, D. Gillatt, D. Sabanathan, 2019, Journal of Clinical Oncology.

MILGa-01: A first-in-human study assessing the safety and tolerability of chMIL-38 in metastatic prostate, bladder, and pancreatic cancers.

D. Gillatt, D. Sabanathan, K. Thurecht, 2017 .

Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life

Joyce E. Wilkinson, T. Peters, P. Fayers, 2016, BJU international.

Factors associated with trial recruitment, preferences and treatments received were elucidated in a comprehensive-cohort study.

T. Peters, F. Hamdy, D. Neal, 2019, Journal of clinical epidemiology.

Contemporary radical cystectomy outcomes in patients with invasive bladder cancer: a population‐based study

David P. Smith, D. Gillatt, Manish I. Patel, 2015, BJU international.

Design of a multi-DOF cable-driven mechanism of a miniature serial manipulator for robot-assisted minimally invasive surgery

Anthony G. Pipe, Chris Melhuish, Antonia Tzemanaki, 2016, 2016 6th IEEE International Conference on Biomedical Robotics and Biomechatronics (BioRob).

μAngelo: A novel minimally invasive surgical system based on an anthropomorphic design

Anthony G. Pipe, Chris Melhuish, Antonia Tzemanaki, 2014, 5th IEEE RAS/EMBS International Conference on Biomedical Robotics and Biomechatronics.

Pseudo-pseudocysts of the pancreas.

D. Gillatt, R. Williamson, M. Cooper, 1986, Pancreas.

1052 RECENT TRENDS IN INCIDENCE AND MORTALITY OF PENILE CANCER IN ENGLAND

D. Gillatt, J. Verne, R. Persad, 2007 .

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial

J. Oxley, F. Hamdy, J. Donovan, 2017, European urology.

PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer

D. Gillatt, J.‐P. Meyer, 2002, Prostate Cancer and Prostatic Diseases.